Jerry D Estep, MD; Husam M Salah, MD; Samir R Kapadia, MD; Daniel Burkhoff, MD, PhD; Anuradha Lala, MD; Javed Butler, MD, MPH, MBA; Shelley Hall, MD; Marat Fudim, MD, MHS
J Card Fail. 2024 DOI: https://doi.org/10.1016/j.cardfail.2024.07.007
Published September 2024
Supporting Materials
Top 10 Takeaways
- Device-based therapies are becoming integral in managing HF
- This is a rapidly growing field with many devices gaining approval by the regulatory agencies
- Devices offer a promising avenue to address the high residual risk in HF
- Guideline-directed medical therapy includes both drug and selected device-based therapies.
- These classes of therapy should be considered synergistic rather than in competition to each other
- Device based therapies can overcome certain limitations of drug therapy (e.g., adherence and tolerance), and effectively target some of the HF-related pathophysiologic alterations that may not be amenable to pharmacological therapy
- Device based therapies span both diagnostic and therapeutic approaches
- There is a need for better identification of the ideal patient population by employing clinical, hemodynamic, and structural phenotyping of HF
- There is a need for a systematic approach to integrate device interventions into the HF management workflow through evidence-based sequencing strategies is crucial
- Device based therapies in HF is a team based discipline that requires in many cases cross-silo collaboration
Press Release
The Case for Integrating Novel Device-Based Therapies into Guideline Directed Medical Therapy for the Treatment of Heart Failure
WASHINGTON, DC (SEPTEMBER 10, 2024) - Novel device-based therapies may overcome limitations of pharmacologic therapies for some patients living with heart failure (HF), indicating that a synergistic approach between the two therapies is ideal for implementation of guideline directed medical therapy (GDMT). The Heart Failure Society of America (HFSA) Scientific Statement: Update on Device Based Therapies in Heart Failure, published today in the Journal of Cardiac Failure (JCF), provides a state-of-the-art scientific overview and update of the rapidly evolving field of device-based therapies for HF, including a clinical pathway to implementation of these technologies alongside pharmacologic therapies.